Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
After 52 weeks’ treatment, 47.8% of patients receiving anifrolumab were judged to have a BICLA response ... including pain, rashes, fatigue, swelling in joints and fevers, and is associated ...
Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
“The results demonstrate that anifrolumab achieved a statistically significant reduction in overall disease activity, as well as statistically significant reductions in both the requirement to use ...
AstraZeneca has completed the resurrection of its anifrolumab drug for systemic ... joint swelling, rashes, pain and fatigue, and an increased risk of death from infection and heart disease ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
Hosted on MSN28d
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback